The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
UTD2 is the world's first oral epothilone microtubule inhibitor
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The drug will be available in 600 hospitals and 105 DTPs
Avacc 3 has significant advantages over existing whooping cough vaccines
Tislelizumab is now approved for seven indications in China
The medicine is now approved for eight indications across five different types of cancer in China.
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Subscribe To Our Newsletter & Stay Updated
